Abstract:Estrogen receptor α (ERα) drives growth in the majority of human breast cancers by binding to regulatory elements and inducing transcriptional events that promote tumor growth. ERα binding activity largely depends on access to binding sites on chromatin, which is facilitated in part by Pioneer Factors (PFs). Transcription factors operate in complexes through thousands of genomic binding sites in a combinatorial fashion to control the expression of genes. However, the extent of crosstalk and cooperation between ERα pioneer factors and more collaborative transcription factors in breast cancer still remains to be elucidated systematically. Methods: Here, we determined the genomic binding information of 40 transcription-related factors and histone modifications with ChIP-seq in ENCODE and integrated it with other genomic information (RNA-seq, ATAC-seq, Gene microarray, 450k methylation chip, GRO-seq), forming a multi-dimension network to illuminate ERα associated transcription. Results: We show that transcription factor, NR2F2 binds to most sites independently of estrogen. Perturbation of NR2F2 expression decreases ERα DNA binding, chromatin openning, and estrogen-dependent cell growth. In the genome-wide analysis, we show that most binding events of NR2F2 and known pioneer factors FOXA1, GATA3 occur together, covering 85% of the ERα binding sites. Regions bound by all the three TFs appeared to be the most active, to have the strongest ERα binding and to be enriched for the super enhancers. Conclusions: The ERα binds to pre-accessible sites containing ERE elements bound by the three transcription factors (NR2F2, FOXA1 and GATA3).The three genes were also identified to correlate with decreased metastatic potential in patient cohorts and co-regulate each other. Together, our results suggest that NR2F2 is a cofactor with FOXA1 and GATA3 in ERα-mediated transcription.

Distribution characteristics of terrestrial heat flow density in Jiyang depression of Shengli Oilfield, East China

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

3d-Qsar And Docking Studies Of Estrogen Compounds Based On Estrogen Receptor Beta

Advances in Estrogen Receptor Β Coregulator

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Research Advance on a Novel Estrogen Receptor β

Cooperativity of Co-Factor NR2F2 with Pioneer Factors GATA3, FOXA1 in Promoting ERα Function

Progress in study of selective ERβ ligands

Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription

Transcriptional Activation of Nuclear Estrogen Receptor and Progesterone Receptor and Its Regulation.

Structural Insights into the Specificity of Ligand Binding and Coactivator Assembly by Estrogen-Related Receptor Β

Progress on Estrogen Receptor and Female Reproduction

Genome-Wide Mapping Of In Vivo Er Alpha-Binding Sites In Male Mouse Efferent Ductules

Transcriptional Activation Of Nlp By Estrogen-Er Alpha In Breast Cancer

Genome-Wide Investigation of Genes Regulated by ERα in Breast Cancer Cells.

Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application

Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy

Role of estrogen receptor in breast cancer cell gene expression.

Eukaryotic Expression Vectors Construction and Transcriptional Ac tivity Analysis of Different Isoforms of ERβ in Breast Cancer

ER is an RNA-binding protein sustaining tumor cell survival and drug resistance